Compare Abbott Laboratories (ABT) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Baker Hughes Co — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while Baker Hughes Co trades at $57.13 (market cap $54.04B). The key difference: Abbott Laboratories is far larger — about 3.1× Baker Hughes Co's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BKR | |
|---|---|---|
Market Cap | $166.94B | $54.04B |
Sector | Health | Energy |
52-Week High | $136.62 | $69.67 |
52-Week Low | $82.57 | $38.68 |
Enterprise Value | $193.69B | $55.44B |
Dividend Yield | 2.63% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Baker Hughes (BKR) trades at $54.47, up 3.2% over the past 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Recent contract wins in Angola and Nigeria, along with expansion into geothermal energy, highlight growth initiatives. Financials show strong profitability with an 11.17% net income margin and improving cash flow trends, though revenue growth has moderated.
The outlook for BKR is positive, supported by analyst consensus with a $74.27 price target and 66.7% buy ratings. Key opportunities include energy transition projects and international contracts, while risks involve oil price volatility and integration challenges from the Chart Industries acquisition. The stock presents a value opportunity with a P/E of 17.01, trading below analyst targets amid operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
